Purchase this article with an account.
Andreas Jekle, Suriani Abdul Rani, Chris Celeri, Meghan Zuck, Ping Xu, Lu Wang, Kathryn Najafi-Tagol, Mark Anderson, David Stroman, Dmitri Debabov; Broad-Spectrum Virucidal Activity of (NVC-422) N,N-dichloro-2,2-dimethyltaurine against Viral Ocular Pathogens In Vitro. Invest. Ophthalmol. Vis. Sci. 2013;54(2):1244-1251. doi: 10.1167/iovs.12-10700.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Viral conjunctivitis is a highly contagious infection often causing major epidemics. A safe broad-spectrum antiviral agent is needed to treat this unmet medical need. The purpose of this study is to demonstrate that in vitro NVC-422 is a safe, broad-spectrum topical virucidal agent with activity against ophthalmic viral pathogens.
The virucidal activity of NVC-422 against several serotypes of human adenovirus (HAdV), coxsackievirus A24, enterovirus 70, and herpes simplex-virus-1 (HSV-1) was tested in standard in vitro titer reduction assays with or without tears. An in vitro irritancy score for NVC-422 was determined using the MatTek EpiOcular tissue system.
NVC-422 reduced the viral titer of HAdV-5, HAdV-8, HAdV-19, HAdV-37, and HSV-1 by at least 4 logs after 1 hour incubation at 250 μM. Incubation of coxsackievirus A24 and enterovirus 70 with 2.5 mM NVC-422 for 1 hour reduced the viral titer by 4 logs and 4.5 logs, respectively. The virucidal activity of NVC-422 is maintained in the presence of 10% synthetic tears. In the EpiOcular corneal tissue model, NVC-422 was nonirritating at concentrations up to 41 mM.
NVC-422 has potent, rapid in vitro virucidal activity against major causes of conjunctivitis. Its broad-spectrum virucidal activity combined with favorable safety profile validates NVC-422 as a potential new therapeutic agent against viral conjunctivitis.
This PDF is available to Subscribers Only